1. Atrial fibrillation; 
2. Subject underwent cardiac pacemaker treatment; 
3. Subject underwent metal graft treatment; 
4. Claustrophobia; 
5. Acute myocardial infarction, cardiac ischemia indicated by 6-minute walk test, hypertrophic cardiomyopathy, constrictive pericarditis, significant valve disease or congenital heart disease, severe pulmonary hypertension; 
6. Ischemic heart failure without the revascularization or undergone the revascularization within last 6 months; 
7. Subject underwent cardiac surgery or cerebrovascular events within the previous six months; 
8. Subjects who plan to have cardiac transplantation; 
9. Severe hepatic and renal insufficiency (serum creatinine>2.0 mg /dl, AST or ALT is five times higher than the upper limit of normal range); 
10. Subject needs mechanical ventilation; 
11. Systolic blood pressure < 90mmHg, or > 160mmHg; 
12. Chronic heart failure complicated with acute hemodynamic disturbance or acute decompensation within last 1 month; 
13. Mobitz Type II or III° atrial ventricular block，severe ventricular arrhythmia (polymorphic and frequent premature ventricular beats, frequent non-sustained ventricular tachycardia); 
14. Serum potassium<3.2mmol/L, or>5.5mmol/L; 
15. Female subject is pregnant or plan to become pregnant 
16. Childbearing-aged female subject who is unmarried or dose not bear child; 
17. Subject with life expectancy less than 6 months as assessed by investigators; 
18. Subject participated in any other clinical trial within the previous three months; 
19. Subject with previous history of tumor, or current tumor patient, or subject with pre-cancerous disease manifested by pathological examination (such as ductal carcinoma in situ or cervical epithelial dysplasia) 
20. Examinations (physical examination, X-ray examination, type-B ultrasonic detection or other methods) reveal that the subject has malignant mass, gland hyperplasia or adenoma with endocrine activity, or impact on heart, or endocrine function (such as pheochromocytoma, thyroid enlargement); 
21. The Investigator deemed for whatever reason that the subject is not likely to complete the study or comply with the study procedures (due to administration or any other reason).       
    

NCT01214096_exc_T1
Condition
Atrial fibrillation
NCT01214096_exc_T2
Procedure
cardiac pacemaker treatment
NCT01214096_exc_T3
Device
cardiac pacemaker
NCT01214096_exc_T4
Procedure
metal graft treatment
NCT01214096_exc_T5
Device
metal graft
NCT01214096_exc_T6
Condition
Claustrophobia
NCT01214096_exc_T7
Condition
Acute myocardial infarction
NCT01214096_exc_T8
Condition
cardiac ischemia
NCT01214096_exc_T9
Procedure
6-minute walk test
NCT01214096_exc_T10
Condition
hypertrophic cardiomyopathy
NCT01214096_exc_T11
Condition
constrictive pericarditis
NCT01214096_exc_T12
Condition
valve disease
NCT01214096_exc_T13
Qualifier
significant
NCT01214096_exc_T14
Condition
congenital heart disease
NCT01214096_exc_T15
Condition
severe pulmonary hypertension
NCT01214096_exc_T16
Qualifier
severe
NCT01214096_exc_T17
Qualifier
congenital
NCT01214096_exc_T18
Scope
6-minute walk test, hypertrophic cardiomyopathy, constrictive pericarditis, significant valve disease or congenital heart disease, severe pulmonary hypertension
NCT01214096_exc_T19
Scope
Acute myocardial infarction, cardiac ischemia
NCT01214096_exc_T20
Condition
Ischemic heart failure
NCT01214096_exc_T21
Procedure
revascularization
NCT01214096_exc_T22
Negation
without
NCT01214096_exc_T23
Procedure
revascularization
NCT01214096_exc_T24
Temporal
within last 6 months
NCT01214096_exc_T25
Scope
without the revascularization or undergone the revascularization within last 6 months
NCT01214096_exc_T26
Procedure
cardiac surgery
NCT01214096_exc_T27
Condition
cerebrovascular events
NCT01214096_exc_T28
Temporal
within the previous six months
NCT01214096_exc_T29
Scope
cardiac surgery or cerebrovascular events
NCT01214096_exc_T30
Procedure
cardiac transplantation
NCT01214096_exc_T31
Observation
plan
NCT01214096_exc_T32
Condition
renal insufficiency
NCT01214096_exc_T33
Condition
hepatic insufficiency
NCT01214096_exc_T34
Measurement
serum creatinine
NCT01214096_exc_T35
Value
>2.0 mg /dl
NCT01214096_exc_T36
Measurement
AST
NCT01214096_exc_T37
Measurement
ALT
NCT01214096_exc_T38
Value
five times higher than the upper limit of normal range
NCT01214096_exc_T39
Scope
AST or ALT
NCT01214096_exc_T40
Scope
hepatic and renal insufficiency
NCT01214096_exc_T41
Procedure
mechanical ventilation
NCT01214096_exc_T42
Measurement
blood pressure
NCT01214096_exc_T43
Value
< 90mmHg
NCT01214096_exc_T44
Value
> 160mmHg
NCT01214096_exc_T45
Scope
< 90mmHg, or > 160mmHg
NCT01214096_exc_T46
Condition
Chronic heart failure
NCT01214096_exc_T47
Condition
acute hemodynamic disturbance
NCT01214096_exc_T48
Condition
acute decompensation
NCT01214096_exc_T49
Temporal
within last 1 month
NCT01214096_exc_T50
Scope
acute hemodynamic disturbance or acute decompensation
NCT01214096_exc_T51
Measurement
Mobitz
NCT01214096_exc_T52
Value
Type II or III
NCT01214096_exc_T53
Condition
atrial ventricular block
NCT01214096_exc_T54
Qualifier
severe
NCT01214096_exc_T55
Condition
ventricular arrhythmia
NCT01214096_exc_T56
Observation
premature ventricular beats
NCT01214096_exc_T57
Condition
ventricular tachycardia
NCT01214096_exc_T58
Qualifier
non-sustained
NCT01214096_exc_T59
Multiplier
frequent
NCT01214096_exc_T60
Measurement
Serum potassium
NCT01214096_exc_T61
Value
<3.2mmol/L
NCT01214096_exc_T62
Value
>5.5mmol/L
NCT01214096_exc_T63
Scope
<3.2mmol/L, or>5.5mmol/L
NCT01214096_exc_T64
Multiplier
frequent
NCT01214096_exc_T65
Qualifier
polymorphic
NCT01214096_exc_T66
Scope
polymorphic and frequent premature ventricular beats, frequent non-sustained ventricular tachycardia
NCT01214096_exc_T67
Person
Female
NCT01214096_exc_T68
Condition
pregnant
NCT01214096_exc_T69
Observation
plan
NCT01214096_exc_T70
Condition
pregnant
NCT01214096_exc_T71
Person
female
NCT01214096_exc_T72
Observation
unmarried
NCT01214096_exc_T73
Observation
bear child
NCT01214096_exc_T74
Negation
not
NCT01214096_exc_T75
Value
less than 6 months
NCT01214096_exc_T76
Observation
life expectancy
NCT01214096_exc_T78
Condition
tumor
NCT01214096_exc_T79
Observation
previous history
NCT01214096_exc_T80
Condition
tumor
NCT01214096_exc_T81
Temporal
current
NCT01214096_exc_T82
Condition
pre-cancerous disease
NCT01214096_exc_T83
Procedure
pathological examination
NCT01214096_exc_T84
Condition
ductal carcinoma in situ
NCT01214096_exc_T85
Condition
cervical epithelial dysplasia
NCT01214096_exc_T86
Scope
ductal carcinoma in situ or cervical epithelial dysplasia
NCT01214096_exc_T87
Procedure
physical examination
NCT01214096_exc_T88
Procedure
X-ray examination
NCT01214096_exc_T89
Procedure
type-B ultrasonic detection
NCT01214096_exc_T90
Procedure
other methods
NCT01214096_exc_T91
Scope
physical examination, X-ray examination, type-B ultrasonic detection or other methods
NCT01214096_exc_T92
Procedure
Examinations
NCT01214096_exc_T94
Condition
malignant mass
NCT01214096_exc_T95
Condition
gland hyperplasia
NCT01214096_exc_T96
Condition
adenoma
NCT01214096_exc_T97
Condition
endocrine activity
NCT01214096_exc_T98
Qualifier
with endocrine activity
NCT01214096_exc_T99
Condition
pheochromocytoma
NCT01214096_exc_T100
Condition
thyroid enlargement
NCT01214096_exc_T101
Condition
impact on endocrine function
NCT01214096_exc_T102
Condition
impact on heart
NCT01214096_exc_T103
Scope
impact on heart, or endocrine function
NCT01214096_exc_T104
Scope
pheochromocytoma, thyroid enlargement
NCT01214096_exc_T105
Scope
malignant mass, gland hyperplasia or adenoma with endocrine activity, or impact on heart, or endocrine function (such as pheochromocytoma, thyroid enlargement)